New radiation technique aims to spare rectal cancer patients from surgery

NCT ID NCT07337876

Recruiting now Disease control Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special MRI-guided radiation machine (MR-linac) can deliver high-dose radiation precisely to rectal tumors, allowing patients to avoid surgical removal of the rectum. About 100 people with early-stage rectal cancer will receive this radiation along with standard chemotherapy. The main goal is to see if patients can live without needing rectal surgery for at least two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dose escalated radiotherapy with MRI guidance (MR-linac) plus standard chemotherapy
What this could lead to: If successful, this approach could allow many rectal cancer patients to keep their rectum and avoid major surgery, improving quality of life.
What could go wrong: This is a phase 2 trial with only 100 participants, so results may not apply to everyone. The treatment may not control the cancer as well as surgery, and there are risks from radiation and chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER

Contacts and locations

Locations

University Hospital Tübingen
RECRUITING

Tübingen, Baden-Wurttemberg, 72074, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.